SXTP Stock Forecast & Price Target

60 Degrees is facing a temporary decrease in product sales for Q1 FY26 due to higher returns and a lower sell-through for their ARAKODA regimen. This has resulted in reduced revenue and a net loss for the quarter, leading to a decrease in earnings per share. However, with a solid pipeline and partnerships in place for future product releases, the company has potential for growth in the long term. There are some risks to consider, such as potential dilution from future capital raises and low visibility on regulatory approval, but overall the positive outlook for the company's growth prospects and upside potential outweighs the risks.

60 Degrees is facing multiple challenges, including a lack of visibility on their ongoing clinical development and financial constraints due to ongoing expenses. This has led us to downgrade our rating to Neutral, as we believe it will be difficult for the company to successfully execute their trials without significant changes such as partnering or raising funds. While we acknowledge the company's potential in the infectious disease market, their current financial situation and lack of visibility make it difficult for us to maintain a positive outlook.